StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
ONE.AX$0.17-8.33%
Fair $0.17+0.0%

ONE.AX

Oneview Healthcare PLC

Healthcare / Health Information ServicesASX

$0.17

-0.02 (-8.33%)

Fairly Valued+0.0%Fair Value $0.17Fund rank 31/100 · Data gapFallback financials|
SA 19/F
F-Score: 1/9
Low Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 33% · confianza 25%

FCF escenarios

weak_data · normalized FCF $-8.5M · quality 76.3/100

Data gap 31/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 47/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

19/100

F

Piotroski

1/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 1unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified. ROE is -3.5%, below the 5% threshold
Thesis & Journal · ONE.AXLocal privado en este navegador · Oneview Healthcare PLC
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$145M

P/E

N/A

•

EV/EBITDA

N/A

•

ROE

-345.4%

↓

Gross Margin

63.9%

↑

Debt/Equity

0.30

↑
52-Week Range$0
$0$0

TradingView lightweight chart

ONE.AX price, volumen y niveles de valoración

Último $0.165Periodo -95.5%
Fair value: $0.165

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+10.4%

FCF CAGR

—

FCF margin

-70.7%

FCF / Net income

0.67x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $12.0M · net income $-12.6M · FCF $-8.5M

2022-FY → 2025-FY

Gross margin

63.9%+4.0% pts

Operating margin

-96.4%+47.7% pts

Net margin

-104.9%+16.9% pts

FCF margin

-70.7%+29.7% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$12.0M$12.0M$9.9M$9.4M$8.9M
Net Income$-12.6M$-12.6M$-10.8M$-8.9M$-10.9M
EBITDA$-10.5M$-10.5M$-10.1M$-7.9M$-10.1M
EPS-0.02-0.02-0.02-0.02-0.02
Gross Margin63.9%63.9%67.4%65.6%59.9%
Operating Margin-96.4%-96.4%-120.1%-94.3%-144.1%
Net Margin-104.9%-104.9%-109.5%-95.1%-121.8%
Balance Sheet
Debt/Equity0.300.300.090.100.24
Current Ratio1.301.30———
Cash Flow
Free Cash Flow$-8.5M$-8.5M$-10.9M$-7.8M$-9.0M
Returns
ROE-345.4%-345.4%-81.8%-97.8%-481.7%
Valuation
P/B34.6434.6415.5015.4622.68
Growth & Yield
Revenue Growth21.3%21.3%5.3%5.3%—
EPS Growth-4.4%-4.4%-3.9%24.0%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -38.9%

Total return

-38.9%

Start / end P/E

n/dx → n/dx

EPS bridge

-0.02 → -0.02

Residual

-38.9%

EPS growthn/d
Multiple reratingn/d
Dividend+0.0%
Residual / FX / buybacks / cross-term-38.9%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.